Blog

Experts on Sickle Cell Disease and Cancers have converged to exchange ideas and promote collaborative efforts at the 2^ND Annual Scientific Symposium of the International Research Center of Excellence (IRCE).

At the two-day symposium, the Dean of the University of Maryland School of Medicine, Baltimore, USA, Dr. Mark Gladwin, said that Nigeria has the most babies born with Sickle Cell Disease than any country of the world.

Dr Gladwin, an expert in Sickle Cell Disease and Pulmonary Hypertension, added that “Often, Sickle Cell Disease is put on lower priority than HIV, malaria and tuberculosis because Africa faces many infectious health challenges. In the same way that we see that HIV is controlled with medications, medications are being developed for sickle cell. What is important is to identify a baby with sickle cell early.”

He recommended the use of hydroxyurea to reduce the damaging effects of sickle cell on organs and prevent complications that may occur in adulthood.

“Hydroxyurea has a very big effect. It improves survival and reduces painful attacks and organ damage. It is not a cure but it makes a significant impact,” the Dean said.

He noted that with the progress of science, more new therapies are being developed for sickle cell disease.

Dr. Gladwin said that the University of Maryland ‘s long standing partnership with Nigeria through the Institute of Human Virology Nigeria (IHVN) in HIV, tuberculosis and malaria will be leveraged upon to address non-communicable diseases like cancer, hypertension and sickle cell disease.

Earlier, IHVN Chief Executive Officer, Dr. Patrick Dakum welcomed both local and international experts to the symposium and said that the Institute is expanding its partnerships among public, private and faith-based organizations.

“In terms of partnerships, ever since we started in 2024, we engaged both the public and private sector. In terms of the grants that we are currently implementing with several actors, we are seeking partnerships with both local and international institutions,” Dr Dakum said.

IRCE Executive Director, Prof. Alash’le Abimiku expressed optimism that the meeting will foster relationships to drive scientific innovation and progress. She said the center will continually strive to be “a fertile ground for discovery, collaboration and development of young talents, while promoting ethical conduct of research for the benefit of local and international communities.”

In fostering an excellent work culture and staff performance, the Executive Management of the Institute of Human Virology Nigeria (IHVN) has initiated the “Employee Recognition Awards” to recognise “Employees of the Month” and “Employee of the Year.”

According to the IHVN Director of Finance and Administration, Mr. Olu Alabi, this recognition covers overall employee performance in dressing, innovation, teamwork, productivity, efficiency, leadership & interpersonal skills, punctuality and adherence to company values and principles amongst others.

For July 2024, IHVN Celebrates, Zayyan Bello, Temitope Olukomogbon, Judith Arachie, Adeyemo Adeyemi, Chieme Ogumka, Chigozie Ezinne Nwafor, Nakom Kefas, Pantong Gershon Daskyakar, Fredrick Saiki, Yop Tenmang, whose performance stood out in their teams.

Three hearty cheers to our July star performers!

The International Research Center of Excellence (IRCE) at the Institute of Human Virology Nigeria (IHVN) is set to host its 2^nd Annual Scientific Symposium on “Expanding Partnerships to Sickle Cell Disease (SCD) and Cancer Research” from August 14^th to 15th at the IHVN Campus in Abuja.

The two-day event will feature extensive presentations and discussions on health research in sickle cell disease and cancer and will include the diagnosis, care, treatment, and innovative applied research. The two-day symposium will bring together local and international experts such as the Dean of the University of Maryland School of Medicine (UMB-SOM), Prof. Mark T. Gladwin, and Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), Prof. Taofeek K. Owonikoko who are accompanied by several senior faculty from UMB-SOM already involved in research activities in Nigeria.

Nigerian experts such as Dr. Obi Adigwe DG NIPRD, Prof Obigelli Nnodu and Dr. Paul Jibrin from AUTH, Dr Tola Adewole from NSIA, and several representatives from pharma and industry will also participate as speakers. Industrial partners will also have exhibitions booths.

Special Guest at the symposium, Dean Gladwin is an expert in pulmonary hypertension and sickle cell disease (SCD), Prof Gladwin’s research identified a novel disease mechanism, named hemolysis-associated endothelial dysfunction that brought attention to the resistance to nitric oxide in patients with diseases like sickle cell and, malaria. His studies on hemolysis-associated endothelial dysfunction have enabled the clinical and epidemiological characterization of a human disease syndrome known as hemolysis-associated pulmonary hypertension which poses a significant risk to patients with sickle cell anemia. He is currently heading a Phase II clinical trial, conducted across 22 sites in France, Brazil, and the U.S which aims to evaluate the effectiveness of a novel blood transfusion technique that utilizes the patient’s blood to improve outcomes and extend survival in patients with sickle cell disease.

Nigerian-born Prof. Taofeek K. Owonikoko is a distinguished physician and scientist with a specialty in thoracic oncology and translational research. Prof. Owonikoko is the lead oncologist for the University of Maryland School of Medicine (UMSOM) and the University of Maryland Medical Center (UMMC).

IHVN CEO, Dr. Patrick Dakum pointed out that “this year also marks a significant milestone for IHVN as it celebrates its 20th anniversary. Over the past two decades, IHVN has made remarkable strides in HIV/AIDS, TB, and malaria through its two centers – the Center for Public Health Implementation (CPHI) and IRCE; and through strategic collaborations with the government of Nigeria, UMB-SOM and Institute of Human Virology (IHV) Baltimore- IHVN’s initial parent institution, and other institutions. We are excited to continue to extend such fruitful partnership to other key public health diseases such as SCD and Cancer.”

IRCE Executive Director, Prof. Alash’le Abimiku said that since 2016, IRCE has leveraged on CPHI’s extensive programmatic experience and infrastructure to advance IHVN’s research agenda. It’s state of the art core laboratories, biorepository, clinical trial unit, and core of well-trained research staff have facilitated the conduct of ethically and culturally acceptable high-quality research, thus enabling the institution to provide data and evidence required to improve health care and ensure pandemic preparedness.

IRCE is one of the centers at IHVN. It was established in 2015 to promote public/private partnerships for quality research with capacity building. IRCE has been pivotal in pioneering innovative research toward improving healthcare services and building research capacity among young Nigerian investigators. The Center is implementing more than 40 funded research grants in infectious and non-infectious diseases in Nigeria to address local and global health challenges.

According to Prof Abimiku, “This second IRCE symposium builds on the first which was held last year, focused on ‘Addressing Local Health Challenges through Quality Research and Partnerships’ by extending collaboration to two important health challenges that targets the black population – SCD and Cancers. The symposium will be held yearly as an avenue to promote research on issues of public health relevance to Nigeria and the world and will continue to involve the government, research institutions, and our private and industry partners,”